Validation of a graded prognostic model in patients with brain metastases treated with whole-brain radiotherapy instead of radiosurgery

0Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: The aim of this study was to analyze the survival predictions obtained from a recent graded prognostic model developed and validated in Japan. Patients and Methods: This was a retrospective singleinstitution analysis of 249 patients, managed with wholebrain radiotherapy for brain metastases. The sum of scores was calculated as in the Japanese study. The following parameters were included: number of brain metastases, volume of the largest lesion, sex, Karnofsky performance status, primary cancer type, control of primary cancer, and presence of extra-cerebral metastases. Results: Median overall survival was 3.0 months (95% CI= 2.6-3.4 months). The median sum of scores was 12, range=0-29. Statistically significant differences were observed between all prognostic strata. Conclusion: The graded prognostic model is also applicable to patients treated with whole-brain rather than stereotactic radiotherapy.

Cite

CITATION STYLE

APA

Nieder, C., Mannsaker, B., & Yobuta, R. (2021). Validation of a graded prognostic model in patients with brain metastases treated with whole-brain radiotherapy instead of radiosurgery. In Vivo, 35(3), 1569–1572. https://doi.org/10.21873/invivo.12412

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free